First Trust Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

First Trust Advisors’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-39,374	Closed	-$2.15M	–	2522
2018 Q3	$2.15M	Buy	+39,374	New	+$2.69M	﹤0.01%	1625
2018 Q1	–	Sell	-19,095	Closed	-$982K	–	2431
2017 Q4	$982K	Buy	19,095 +12,198	+177%	+$876K	﹤0.01%	1854
2017 Q3	$615K	Buy	+6,897	New	+$524K	﹤0.01%	2020
2017 Q1	–	Sell	-31,260	Closed	-$1.56M	–	2499
2016 Q4	$1.56M	Buy	31,260 +3,148	+11%	+$169K	﹤0.01%	1597
2016 Q3	$1.69M	Buy	+28,112	New	+$1.62M	0.01%	1429

Other funds holding ONCE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

First Trust Advisors's ONCE Position: Q4 2018 in Review

First Trust Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2018, closing a stake of 39,374 shares — an estimated $2.15M sold.

First Trust Advisors first reported a position in ONCE in Q3 2016 and held it in 5 quarters. The position peaked at $2.15M in Q3 2018. 157 funds tracked by Wall St. Rank hold ONCE as of Q4 2018.

First Trust Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
First Trust Advisors sold 39,374 Spark Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $2.15M.
First Trust Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2016 and held it in 5 quarters.
First Trust Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $2.15M in Q3 2018.
157 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2018.

Based on First Trust Advisors's 13F filing for Q4 2018, filed 7 Feb 2019.